Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | ZUMA-11 study overview: axi-cel plus utomilumab in R/R DLBCL

Michael Jain • 8 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Utomilumab
ZUMA-11

Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, gives an overview and update on the ZUMA-11 study of axicabtagene ciloleucel plus utomilumab, an antibody that targets 4-1BB, in patients with refractory diffuse large B-cell lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Michael Jain

Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy 12:30
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
Elizabeth Budde et al. • 13 Apr 2025
Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T 2:13
Lymphoma tumor microenvironment influences toxicity after CD19 CAR-T
Michael Jain • 7 Dec 2019
Does bridging therapy affect lymphoma CAR-T outcomes? 2:25
Does bridging therapy affect lymphoma CAR-T outcomes?
Michael Jain • 8 Dec 2019

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals